{"id":"docetaxel-cisplatin-and-capecitabine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"10-30%","effect":"Mucositis"},{"rate":"50-70%","effect":"Hair loss"},{"rate":"20-40%","effect":"Neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel binds to tubulin, preventing microtubule polymerization and causing cell cycle arrest at the G2/M phase. Cisplatin forms platinum-DNA adducts, triggering apoptosis. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase, leading to DNA damage and cell death.","oneSentence":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Capecitabine is a prodrug of 5-fluorouracil, which inhibits thymidylate synthase, disrupting DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:42.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Adjuvant treatment of node-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":"Nasopharangeal Cancer","enrollment":142},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT06737822","phase":"PHASE3","title":"Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Jodhpur","startDate":"2024-12-20","conditions":"Oral Cancer, Head and Neck Neoplasms","enrollment":346},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT04719988","phase":"PHASE2","title":"Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-01-04","conditions":"Squamous Cell Carcinoma of the Anus Stage III","enrollment":55},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT06156891","phase":"PHASE2","title":"PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-29","conditions":"Oropharyngeal Cancer","enrollment":60},{"nctId":"NCT06156878","phase":"PHASE2","title":"PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT05262335","phase":"PHASE2","title":"Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-12-01","conditions":"Gastrointestinal Tumors","enrollment":116},{"nctId":"NCT04156698","phase":"PHASE2","title":"Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2020-05-21","conditions":"Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy","enrollment":51},{"nctId":"NCT00084734","phase":"PHASE1","title":"Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2002-05","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":61},{"nctId":"NCT02324543","phase":"PHASE1, PHASE2","title":"Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":47},{"nctId":"NCT05953909","phase":"","title":"A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-02-01","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130},{"nctId":"NCT05320874","phase":"PHASE1","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-04","conditions":"Advanced Solid Tumor","enrollment":232},{"nctId":"NCT01459614","phase":"PHASE2","title":"Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-11","conditions":"Pancreatic Cancer","enrollment":44},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT01471470","phase":"PHASE2","title":"Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-07","conditions":"Advanced Gastric Cancer","enrollment":31},{"nctId":"NCT00976976","phase":"PHASE2","title":"Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2007-05","conditions":"Resected Advanced Gastric Cancer","enrollment":46},{"nctId":"NCT03023436","phase":"PHASE3","title":"Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Stomach Neoplasm","enrollment":220},{"nctId":"NCT01967875","phase":"PHASE2","title":"A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer","status":"TERMINATED","sponsor":"China Medical University, China","startDate":"2013-07","conditions":"Stomach Neoplasms","enrollment":27},{"nctId":"NCT02358863","phase":"NA","title":"Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2015-02","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":13},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT03503136","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06","conditions":"Nasopharyngeal Carcinoma","enrollment":632},{"nctId":"NCT03455205","phase":"NA","title":"Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2017-12-24","conditions":"Digestive Tract","enrollment":270},{"nctId":"NCT01472250","phase":"","title":"A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-11","conditions":"Advanced Gastric Cancer","enrollment":498},{"nctId":"NCT03006614","phase":"PHASE3","title":"PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shi Yanxia","startDate":"2016-04","conditions":"Breast Cancer Model, Effects of Chemotherapy, Breast Cancer","enrollment":320},{"nctId":"NCT00454636","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Gastric Cancer","enrollment":158},{"nctId":"NCT02915965","phase":"PHASE2","title":"A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-10","conditions":"Stage II and III Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT02786641","phase":"PHASE3","title":"Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Nasopharyngeal Carcinoma","enrollment":235},{"nctId":"NCT02360501","phase":"PHASE2","title":"Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-01","conditions":"Nasopharyngeal Neoplasms","enrollment":50},{"nctId":"NCT00737438","phase":"PHASE2","title":"Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":22},{"nctId":"NCT02633176","phase":"PHASE3","title":"Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":"Nasopharyngeal Carcinoma","enrollment":120},{"nctId":"NCT01304784","phase":"PHASE1","title":"A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer","status":"COMPLETED","sponsor":"Merrimack Pharmaceuticals","startDate":"2011-01","conditions":"HER-2 Gene Amplification","enrollment":100},{"nctId":"NCT02621970","phase":"PHASE3","title":"Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Nasopharyngeal Carcinoma","enrollment":534},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT01525771","phase":"PHASE1, PHASE2","title":"Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2011-02","conditions":"Stage IV Gastric Cancer With Metastasis","enrollment":37},{"nctId":"NCT00674167","phase":"PHASE2","title":"The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2007-05","conditions":"Gastric Cancer","enrollment":21},{"nctId":"NCT00718913","phase":"PHASE2","title":"Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-04","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT02445209","phase":"PHASE3","title":"Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2010-09","conditions":"HER2 Negative Gastric Cancer","enrollment":56},{"nctId":"NCT00514293","phase":"PHASE2","title":"Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Raghu Nandan, M.D., Inc","startDate":"2007-01","conditions":"Lung Cancer","enrollment":39},{"nctId":"NCT01517009","phase":"PHASE2","title":"A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Jeroen Bosch Ziekenhuis","startDate":"2008-06","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT00454649","phase":"PHASE1","title":"Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Neoplasms","enrollment":102},{"nctId":"NCT00966706","phase":"PHASE2","title":"Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2005-06","conditions":"Pancreatic Cancer","enrollment":105},{"nctId":"NCT00865982","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2008-09","conditions":"Gastric Cancer, Esophageal Cancer","enrollment":50},{"nctId":"NCT00980603","phase":"PHASE2","title":"Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-11","conditions":"Gastric Cancer","enrollment":144},{"nctId":"NCT00845884","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-02","conditions":"Advanced Gastric Cancer","enrollment":49},{"nctId":"NCT00717951","phase":"PHASE2","title":"A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Academy Military Medical Science, China","startDate":"2008-05","conditions":"Advanced Breast Cancer","enrollment":120},{"nctId":"NCT00155259","phase":"PHASE2","title":"Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2004-10","conditions":"Breast Cancer","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TPX induction chemotherapy"],"phase":"phase_3","status":"active","brandName":"docetaxel, cisplatin, and capecitabine","genericName":"docetaxel, cisplatin, and capecitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Capecitabine is a prodrug of 5-fluorouracil, which inhibits thymidylate synthase, disrupting DNA synthesis. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Adjuvant treatment of node-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}